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Abstract
Background: Primary care is the principle setting for depression treatment; yet many older African Americans in
the United States fail to report depressive symptoms or receive the recommended standard of care. Older African
Americans are at high risk for depression due to elevated rates of chronic illness, disability and socioeconomic
distress. There is an urgent need to develop and test new depression treatments that resonate with minority
populations that are hard-to-reach and underserved and to evaluate their cost and cost-effectiveness.
Methods/Design: Beat the Blues (BTB) is a single-blind parallel randomized trial to assess efficacy of a non-
pharmacological intervention to reduce depressive symptoms and improve quality of life in 208 African Americans
55+ years old. It involves a collaboration with a senior center whose care management staff screen for depressive
symptoms (telephone or in-person) using the Patient Health Questionnaire (PHQ-9). Individuals screened positive
(PHQ-9 ≥ 5) on two separate occasions over 2 weeks are referred to local mental health resources and BTB.
Interested and eligible participants who consent receive a baseline home interview and then are randomly
assigned to receive BTB immediately or 4 months later (wait-list control). All participants are interviewed at 4 (main
study endpoint) and 8 months at home by assessors masked to study assignment. Licensed senior center social
workers trained in BTB meet with participants at home for up to 10 sessions over 4 months to assess care needs,
make referrals/linkages, provide depression education, instruct in stress reduction techniques, and use behavioral
activation to identify goals and steps to achieve them. Key outcomes include reduced depressive symptoms
(primary), reduced anxiety and functional disability, improved quality of life, and enhanced depression knowledge
and behavioral activation (secondary). Fidelity is enhanced through procedure manuals and staff training and
monitored by face-to-face supervision and review of taped sessions. Cost and cost effectiveness is being evaluated.
Discussion: BTB is designed to bridge gaps in mental health service access and treatments for older African
Americans. Treatment components are tailored to specific care needs, depression knowledge, preference for stress
reduction techniques, and personal activity goals. Total costs are $584.64/4 months; or $146.16 per participant/per
month.
Trial Registration: ClinicalTrials.gov #NCT00511680
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Depression, a common, debilitating but treatable condi-
tion among older adults, contributes to poor quality of
life and functional decline and is one of the most ser-
ious complications of chronic conditions [1]. Depression
worsens health conditions and exacerbates disability
contributing to a perniciousd o w n w a r ds p i r a l[ 2 ] .E v e n
mild to moderate depressive symptoms are associated
with difficulties performing daily activities and may
amplify and prolong inflammatory responses after infec-
tion [3].
Depression prevalence ranges from 15 to 17%, but
rates are twice as high among individuals with physical
health problems, functional disabilities, low socioeco-
nomic status and receiving home care or related services
[4]. Older African Americans in the United States (USA)
are at particular risk due to high rates of chronic ill-
nesses associated with depression (diabetes, heart dis-
ease), and social, economic and environmental
detriments. Evidence also suggests higher prevalence of
depressive symptoms for this group than previously
reported [5]. The African American Health Study of 998
community-dwelling African Americans found 21.1%
with clinically relevant depressive symptomatology [6].
Of 150 older poor African Americans attending outpati-
ent rehabilitation, 30% scored positively for depression
[7]. A survey of 156 African American senior center
members found 24.2% with mild to moderate severe
depressive symptoms [8].
In the USA, most older adults are screened for depres-
sion and treated in primary care settings, yet frequently
do not receive the recommended standard for depres-
sion care. A consistent finding is that older African
Americans tend to be underdiagnosed in primary care
and underutilize mental health services [9,10,11)]. More-
over, with few exceptions, mental health treatments
have not been developed or evaluated specifically for
older African Americans [12]. However, when depres-
sion treatments including medication and/or cognitive
therapies are provided, outcomes for this group are ben-
eficial and long-lasting [13].
Previously tested system-level depression studies tar-
get primary care settings. These interventions princi-
pally involve collaborative care management
treatments with large trials reporting impressive treat-
ment effects [14-17]. However, these models have not
been developed specifically to outreach to older Afri-
can American communities and, with few exceptions
outcomes have not been evaluated for this group [12].
Also, these models are difficult to sustain due to lim-
itations in clinical and reimbursement structures
unsupportive of care coordination activities essential to
their success.
Moreover, studies consistently show that African
Americans continue to obtain poorer quality of depres-
sion care than White patients [9,10,18,19]. Barriers to
depression care persist at the patient level and include
stigma and lack of depression knowledge [11,20]; provi-
der level due to lack of knowledge and training in
assessment and treatments [9], and systems level due to
lack of care coordination and sustainable infrastructures
[21]. Persistence of mental health disparities for older
African Americans in the USA, higher depression rates
than previously found, coupled with continued unequal
access to culturally relevant mental health treatments,
point to the need to advance more powerful care models
and interventions for this group. Developing and testing
new service approaches that improve access to depres-
sion detection, referral and treatment tailored to treat-
ment preferences of older African Americans remains
an important public health priority [22].
An overlooked and underutilized system of care for
depression detection and treatment is the aging network
of services, a federally and state-funded system in the
USA providing an array of social services to over 9 mil-
lion older adults, many of whom are vulnerable and
underserved [23,24]. One promising depression program
building upon previously tested approaches and offered
through the aging network, Healthy IDEAS (HIDEAS;
Identifying Depression, Empowering Activities for
Seniors), has shown modest positive client outcomes
including enhanced depression knowledge, decline in
symptomatology, and clinician adoption [25,26].
HIDEAS involves systematic screening, depression edu-
cation, referral and linkage and engaging clients in beha-
vioral activation by case managers. Nevertheless,
HIDEAS was not tested in a randomized trial and less
than half (44.7%) of the 94 participants received beha-
vioral activation, with only a small percentage being
African American [26].
A few studies evaluating intervention delivery at home
suggest that older adults pref e rh o m eo v e rc l i n i c - b a s e d
treatment [8], and home sessions may lead to better
treatment acceptance [16], fewer nursing home admis-
sions and in-patient care days, as well as be cost effec-
tive [27].
We designed Beat the Blues (BTB) to be delivered
through a community-based organization such as senior
centers. Senior centers routinely assess older adults for
service needs and health status, serve as initial contact
for a continuum of aging services, and provide a safety
net offering meals, health checks, care management and
referral services. Individuals reluctant to consult primary
care physicians or mental health specialists may be
more comfortable disclosing depressive symptoms to
skilled senior center staff with whom they have rapport.
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of vulnerable older adults at risk for behavioral health
problems, most do not systematically screen for depres-
sive symptoms or offer evidence-based depression treat-
ments. Building senior center capacity to detect
depressive symptoms and deliver effective non-pharma-
cological treatments may compliment other care systems
and optimize mental health programming for
underserved.
BTB builds upon the successes and lessons learned
from prior depression treatment efforts but it also dif-
fers from previous efforts in important ways. First, deliv-
ery is integrated with staffing and daily routines of a
community-based agency, a senior center versus a men-
tal health clinic or primary care setting, enhancing
potential for normalization and sustainability in that set-
ting. Second, BTB is culturally sensitive; its name
reflects the characterization of depression by the target
group; and treatment components resonate with their
preferred coping approaches. As activity is a primary
strategy for coping with adversity among older African
Americans [28], behavioral activation was chosen as an
essential component of BTB. This approach, shown to
be effective in previous depression trials, helps partici-
pants reengage in self-identified meaningful activities.
Third, while each treatment component of BTB has
been shown to be effective in other trials, they have not
been combined into one program and systematically
tested with older African Americans.
BTB is currently being formally evaluated in a pro-
spective parallel two-group randomized trial. The study
is designed as a practical trial embedded in a senior cen-
ter. This article describes trial procedures, the interven-
tion, enrollment, and program costs. Trial results and
cost effectiveness will be reported in future articles.
Methods/Design
The BTB study protocol received ethical approval from
the Institutional Review Board at Thomas Jefferson Uni-
versity (Control #06F.551) in which the protocol was
initiated; with ethical approval also subsequently
received by the Institutional Review Board at Johns
Hopkins University (Control # NA-00046775) upon
appointment of the Principal Investigator and lead
author. Also, a Federal Wide Assurance Agreement
between the senior center agency (Center in the Park)
in which the study was implemented and Thomas Jeffer-
son University was obtained.
BTB reflects a partnership between a university
research center and a senior center with each contribut-
ing to the plan and execution of the study and model
design while preserving internal validity and control of a
randomized trial. Agency staff are trained in human
subjects and participate in recruitment efforts, conduct
depression screenings, and deliver the home interven-
tion; research staff provide oversight of trial procedures,
jointly participate in recruitment efforts, train agency
staff in depression screening, implement randomization
procedures, and provide oversight of intervention deliv-
ery and monitoring of treatment fidelity. The design
optimizes experimental control while building capacity
of the participating senior center to screen and deliver
BTB; hence, maximizing potential for sustainability and
self-sufficiency at trial conclusion if BTB is efficacious
and cost-effective. Additionally, the partnership enables
the senior center to access mental health researchers
and experts to provide oversight and guide implementa-
tion. The academic institution maximizes recruitment
and trial success through involvement upfront of end
users of the intervention. This approach may also
enhance sustainability if the intervention is shown to be
effective.
General procedures include two sequential depression
screenings of individuals by senior center staff over two
weeks using the Patient Health Questionnaire (PHQ-9).
Those eligible (PHQ-9 ≥ 5) and willing provide written
consent using an approved Institutional Review Board
(IRB) form (Thomas Jefferson University IRB control
#06f.551) and receive a baseline home interview con-
ducted by academic partners. Participants are then ran-
domized to receive BTB immediately or 4 months later
(wait-list control). All participants are reassessed at 4
and 8 months by academic partners who remain masked
to study assignment. The design allows for a true two-
group comparison at 4 months to evaluate intervention
effects on symptom severity (primary end point), quality
of life indicators, anxiety, depression knowledge, and
functional disability (secondary endpoints); an evaluation
of long-term (8 months) effects for the initial treatment
group; and whether wait-list controls derive similar ben-
efits from 4 to 8 months. Treatment fidelity is enhanced
through use of treatment manuals, session implementa-
tion checklists, audiotaping and rating of randomly
selected sessions, one-on-one supervision and bi-weekly
group debriefing sessions involving structured case pre-
sentations and review of treatment documentation.
Aims and study hypotheses
Our primary aim is to test the immediate effect of the
intervention at 4-months on symptom severity (PHQ-9
severity score) in African American older adults (pri-
mary trial outcome; between group comparison). Our
hypothesis is that participants in the initial treatment
group will report fewer depressive symptoms in compar-
ison to control group participants receiving usual care.
We also seek to test the maintenance effect of the inter-
vention at 8-months on depression (within group com-
parison). Our hypothesis is that participants in the
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presentation from 4 to 8 months and the wait-list con-
trol group will show similar reductions in depressive
symptoms as the initial treatment group (within group
comparison).
A secondary aim is to evaluate whether BTB has
immediate (4 months) and long-term (8 months) effects
on quality of life indicators, functional difficulty, anxiety,
and depression education and behavioral activation
levels. We expect that the initial treatment group will
show improvements in these areas relative to the wait-
list control group, that improvements will be maintained
at 8 months and that the wait-list control group will
demonstrate similar improvements at 8 months follow-
ing their receipt of the intervention.
Several exploratory aims are also proposed. We will
evaluate the mechanism of action, or pathways, by
which treatment gains are obtained. Given that beha-
vioral activation represents conceptually the key active
ingredient of the proposed intervention, we plan to eval-
uate its mediational effect. We will also evaluate
whether the intervention has a differential treatment
effect based on a study participant’s gender, age, and liv-
ing arrangement (alone or with others). Given that pre-
vious research suggests that participant characteristics
may moderate depressive symptoms and treatment out-
comes, these exploratory analyses will provide insight as
to whether this particular treatment benefits some
groups more than others.
Recruitment, eligibility and randomization
Participants enrolled in the trial were recruited from
two sources, a program providing short-term in-home
support for individuals who are medically comprised
(referred to as the In-Home Support Program; IHSP) or
the community at-large. IHSP provides homebound
elders assistance regaining independence after illness or
hospitalization through home health and homemaker
services, home delivered meals, transportation, or com-
panions but does not typically involve formal and sys-
tematic depression screening. Recruitment from IHSP
involved integrating depression screening in the assess-
ment process of participants in the program. Recruit-
ment to the community at-large involved print media,
presentations to community groups, and print media.
Eligibility criteria for BTB include being African
American; ≥ 55 years of age; English speaking; cogni-
tively intact (MMSE > 24), and a score ≥ 5o nt h e
PHQ-9 on two sequential testing occasions. Other cri-
teria are practical and include having a home telephone
and planning to live in the area for 8 months. Indivi-
duals are not eligible with serious mental illness his-
tories, life-limiting illnesses, involvement in another
clinical depression trial, or if living in assisted living or
nursing home facilities. Individuals receiving anti-
depressant medications or other mental health treat-
ments are eligible.
As individuals from IHSP may be more medically and
functionally compromised than those enrolled from the
community at-large, we used a stratified randomized
design to assure equivalence between groups along this
dimension. Permuted block randomization with each
stratum (IHSP versus other recruitment source) to con-
trol for possible changes over time in subject mix was
employed. The blocking number was developed by the
trial senior statistician and was not disclosed to the
investigative team.
Measures
In selecting measures for this study, we chose those with
known reliability and validity; sensitivity to change that is
expected to occur as a consequence of intervention; rele-
vance to and wide usage in depression research, and
acceptability by the target population. Our primary out-
come measure is the Patient Health Questionnaire (PHQ-
9), a brief, 9-item self-report measure specifically devel-
oped as an assessment tool for the diagnosis of depression
in primary care. In addition to its psychometric soundness
and demonstrated reliability, validity, sensitivity and speci-
ficity, the measure is also widely used in community-based
settings and research trials. It yields a depression severity
score (0 to 27) and a diagnostic category (minimal to
none, mild, moderate, moderate severe, severe) mapping
on to the 9 DSM-IV. Administration involves initially ask-
ing two items (loss of interest; feeling upset, distressed or
depressed). Individuals reporting that either symptom
occurs more than half the time over past two weeks are
administered 7 other items [29]. Thus, two scores can be
derived: symptom severity and categorical diagnosis. We
also consider as a complementary secondary outcome a
change in categorical diagnoses in which we seek to deter-
mine the number of persons who shift to none to minimal
diagnostic category at 4 months. A categorical approach
provides a clinical interpretation of treatment efficacy and
also whether the intervention addresses certain syndromes
better than others (e.g., minor depressive disorder may be
more responsive to the proposed intervention than major
severe depression). While the PHQ-9 is a self-report mea-
sure, self-report has been shown to be highly associated
with clinical determinations. Also, the measure has been
shown to be effective when administered in person or via
telephone. The secondary outcome measures for the trial
are presented in Table 1.
BTB Intervention
Up to 10 one hour sessions occur over 4 months. A
home visit can be replaced with check-in telephone calls
once steady progress is demonstrated. Sessions integrate
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tive and modified in BTB to resonate with cultural pre-
ferences: case management, referral and linkage,
depression education, stress reduction techniques, and
behavioral activation. (Table 2) Critical is tailoring to
participants’ depression knowledge level, care manage-
ment needs, and self-identified goals and behavioral acti-
vation plans.
Initial sessions occur weekly and then bi-weekly. In
session one, building rapport and a therapeutic
relationship begins; also, interventionists assess care
management needs and begin education about depres-
sive symptoms making connections between behavior
and mood. Explained is that with depression, activities
once pleasurable are often stopped which may heighten
symptomatology. Likewise, previously pleasurable activ-
ities may no longer be pleasurable. Interventionists also
discuss sharing depressive symptoms with physicians (if
medication may be necessary or for future considera-
tion) and strategies to use when physicians are of a
Table 1 Secondary Outcome Measures for BTB Trial
Domain Description of Measure # of
Items
Functional
difficulties
Level of difficulty (1 no difficulty to 5 unable to do due to health problem) with items reflecting ambulation, self-care
and instrumental activities of daily living [31].
18
Depression
knowledge
Self-efficacy concerning ability to recognize and treat depression rated from absolutely confident (4) to not confident
at all (1) [32].
10
Behavioral
Activation
Behavioral Activation Scale (Abbreviated) contains items rated on a scale from 0 not at all to 6 completely and
address activation in a range of daily activities (e.g., stayed in bed too long; I accomplished the goals I set out to do
to) [33].
26
Anxiety State Anxiety Scale in which items are endorsed as 1 (very much) to 4 (not at all) [34]. 10
Quality of daily
life
Adapted from the Perceived Change Index, items reflect mood, sleep quality and daily well-being rated from 1
(gotten much worse in past month) to stayed the same (3) to improved a lot (5) [35].
14
Overall quality of
life
Adapted from the Quality of life for Alzheimer’s Disease items are assessed from 1 (poor) to 4 (excellent) concerning
experience of pleasure, hopefulness, positive relationships with family and friends [36].
12
Table 2 Intervention Component, Content, and Modification for Target Population
Component Content Modifications for Target Population
Education
[14,25]
Education provides foundation for introducing other elements of
the intervention. It enhances readiness of individuals to address
emotion-laden concerns. Specifically, education was provided on:
1) depressive symptoms, 2) how to talk to doctor about
symptoms; and 3) relationship of depression to activity and
negative cycle of disengagement
1) Used participant’s words and own labeling to describe
feelings (e.g., “I am feeling blue”).
2) With rapport and only over time, feelings are then labeled as
symptoms of “depression.”
3) Discussed how to talk to a doctor of a different race.
4) Withdrawal of activity related to specific activities person
identified as valued.
5) Used visual mood rating scales and calendars with big print
to minimize vision and literacy challenges.
Care
management
[12,14]
Care management has been found to be more effective than
therapy or medication alone for low income elders for whom
financial, functional disability and lack of social resources may
contribute to depressive symptoms. Specifically this involved: 1)
assessment 2) coordination with other services/care management;
3) problem identification and resolution
1) Considered a wide range of care needs most relevant to this
population including home repairs, financial concerns, home
and neighborhood safety, family conflict.
2) Housing and neighborhood difficulties were evaluated to
determine whether person could remain in setting.
Referral and
linkage
[14,25]
Referrals and linkages are derived from the care management
assessment and may include: 1) physician referral for medication
review and management; 2) link to psychiatric/psychological
follow-up; 3) link to physician for chronic disease management; 4)
referral and linkage to other services (e.g., home repairs, financial
or legal advisors)
1) Referrals made to vetted community-based service providers
sensitive to participants’ resources and cultural preferences.
2) For individuals identified as in need of more mental health
support, helped make bridge to these services
Stress
reduction
Provides immediate, easy-to-learn technique to reduce stress of
person and introduce relationship of action and mood change.
Specific techniques included: 1) deep breathing; 2) counting; 3)
use of music of personal interest
1) Recognition of importance of spirituality and possible
objection to meditation as a stress reduction activity.
2) Use of relaxation CD/Tape with participants who did not want
to participate in deep breathing exercise.
Behavioral
Activation
[14,16,25]
Approach is designed to increase frequency of pleasant events
and provide positive reinforcement. Self-identification of goals/
action plan promotes activation. The approach involves: 1)
identification of valued activities and goals; 2) establishment of
plan of action for goal attainment; 3) monitoring and adjustment
of plan/goals; and 4) identification of new goals and steps to
attain them and reinforcement and validation.
1) Awareness and identification of appropriate community-based
programs and services that could help participants link to
meaningful activities.
2) Use of “Pro/Con” lists and motivational interviewing in
formulation of feasible goals.
3) Link individual to senior center to enable continuation of
activity participation in a planful, structured setting.
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as a basic stress reduction technique and help partici-
pants identify stressful points in the day for its use. In
sessions 2-3, interventionists engage participants in sim-
ple problem solving to resolve identified care manage-
ment needs (medical, housing repairs, relocation needs,
social, benefits/entitlements), and works on a care man-
agement plan involving coordination, referral and lin-
kages to other services if necessary. Other stress
reduction techniques (counting, music) are introduced
to provide additional tools. In sessions 4-5, intervention-
ists continue addressing care management needs and
introduce behavioral activation. Interventionists review
daily routines and help participants select a goal and
specific activity to add pleasure and personal satisfac-
tion. Active problem solving and motivational interview-
ing techniques help participants achieve identified
activity goals. Potential barriers in carrying out activities
are identified and solutions derived which may also
require care management (arranging transportation) to
engage in desired activities. Sessions 6-8 involve reinfor-
cement of activity engagement, identification of new
activity goals and specific steps to achieve them. In ses-
sions 9-10, interventionists review and reinforce all tech-
niques, help participants identify and use behavioral
activation strategies, and obtain closure. Approximately
6-7 sessions are devoted to behavioral activation.
Wait-list control group
The control group does not receive any study-related
contact following the baseline interview. After comple-
tion of the 4-month reassessment, participants in this
group receive the entire BTB intervention as delivered
to the initial treatment group.
Analytic plan
We based our sample size calculation on the following
assumptions: a) one primary outcome (severity of
depressive symptoms); b) treatment effect sizes reported
in previously published intervention studies testing one
or more components of the intervention we employ in
BTB (effect sizes range from .70 at 6 months and .35 at
12 months in one trial
16 t o. 4 0a t3a n d6m o n t h sa n d
.60 at 12 months for another trial
14); c) ability to detect
a medium effect size of Cohen’sd=0 . 4 0 ;a n dd )t y p eI
error rate of .05 for the single primary hypothesis. A lar-
ger effect size may not be plausible, whereas a smaller
effect size brings us at or near levels where the study
could have statistical but not clinical significance. In
order for this brief, targeted intervention to be worth
implementing in a service context, it must yield more
than trivial effects. Since our planned analyses are pri-
marily analysis of covariance, we calculated the power of
a two-sample t-test. Because we will use analysis of
covariance to adjust for baseline values, we expect to
have adequate precision and power. To attain 90%
power for a two-sided alternative hypothesis using a t-
test to compare the two treatment groups with respect
to 4-month values require 172 study participants for an
effect size of .40. We planned to recruit an additional 20
participants for a total of 192 participants (96 per
group). The additional study participants allowed for a
conservative estimated attrition rate of 10%. To obtain
the necessary sample size of 172, we needed to enroll
192 study participants. The statistical power for second-
ary analyses is the same as for the primary; 90% for a
0.40 effect size with 5% two-tailed tests. Although we
did not conduct power calculations for exploratory
aims, these analyses are important in order to refine
research questions and hypotheses worthy of future con-
sideration, refinement of the intervention and its
dissemination.
The focus of the primary analysis is to examine the
effect of the intervention on symptom severity based on
the principle of “intention to treat.” That is, all subjects
assigned to the initial treatment group will be part of
the primary analyses regardless of the actual number of
intervention contacts received. This approach tests the
effects of the intervention without accounting for the
extent to which study participants actually receive the
intervention. It effectively penalizes the intervention if
subjects are not willing to receive it or if subjects receive
different doses or exposure to treatment. We will calcu-
late adjusted mean differences in treatment effects on
the outcome measure at 4-months using analysis of cov-
ariance. We will include as covariates the baseline value
of the outcome measure and the stratification variable
(recruitment source). Other background characteristics
may also be used as covariates if large or statistically sig-
nificant differences between initial treatment and wait-
list control group participants are found for those vari-
ables in analyses conducted prior to any efficacy ana-
lyses. Prior to conducting the ANCOVA, we will test
the normality assumption for the dependent measure by
examining the distribution of the residuals. If the resi-
dual distribution is skewed, we will use a transformation
of the data.
For purposes of reporting results, we will also com-
pute proportions improved. We will use two definitions
of improvement: any reduction in PHQ-9; a reduction
sufficient to move the patient at least one severity cate-
gory lower. Note that we do not have to worry about
the no symptom (0-4) at baseline group in this defini-
tion, as that group is not eligible. The comparison of
treatment to wait-list control will be with odds ratio and
95% confidence intervals. We will also examine clinical
significance by conducting subsidiary analyses that
examine the proportion of individuals in treatment
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Finally, in another set of analyses we will incorporate
measures of the extent to which treatment has been
received to evaluate relationship of dose/intensity to
treatment outcome. This is for reporting purposes and
we are not powering for these alternative endpoints.
As to our second aim, we seek to evaluate whether
participants in the initial treatment group maintain
reduced symptom presentation from 4 to 8 months. We
view retention as a one-sided concept such that any
beneficial effect of the intervention at four months is
improved or at least maintained at 8 months. Lack of
retention is then considered a non-trivial loss of benefit.
In the language of clinical treatment trials, this is a
“clinical equivalence” or “non-inferiority” hypothesis.
Thus, our analyses for our second aim will focus on
estimating the amount of 4-month benefit that is
retained at 8 months for the treatment group only. We
will use confidence intervals in reporting results in
order to understand how much loss of benefit is consis-
tent with the data we obtain. Given that the main out-
come measure, PHQ-9, has cut off points related to
DSM IV depression conditions (e.g., dysthymia, major
depression), we will be able to evaluate loss of benefit
and retention of effect within the treatment group based
on clinically relevant features.
For exploratory aims, we seek to evaluate the media-
tional role of behavioral activation. We will use separate
regressions in which the first regression will evaluate the
relationship between 4 month values of the behavioral
activation scale (the mediator) and symptom severity as
measured by the PHQ-9 at 4 months. The second
regression will evaluate the relationship between group
assignment (the independent predictor variable) and
symptom severity at 4-months (PHQ-9, the criterion).
The third regression will evaluate the relationship of
treatment assignment (predictor) to PHQ-9 severity
scores (criterion) after entering behavioral activation
values (mediator). To evaluate the strength of the med-
iation effects, we will compute the ratio of the unstan-
dardized betas for treatment assignment (beta from
regression III divided by beta from regression II) with
values less than 1.00 indicating potential mediation. We
will repeat these analyses using 8-month values of the
PHQ-9. Another exploratory aim is to evaluate whether
the intervention has a differential treatment effect based
on a study participant’s gender, age, or living arrange-
ment (alone/with others), factors which have been
shown to be differentially related to depression. To eval-
uate differential treatment effects at 4-months, we will
u s eas i m i l a ra n a l y t i cs t r a t e g ya sf o rt h em a i ne f f e c t
model. ANCOVAs will be used in which the covariates
will be the baseline value and specific participant char-
acteristic (e.g., male/female; live with other or alone; age
60-64 versus 75+). We will then add an interaction term
of group assignment by participant characteristic.
Cost analysis
Economic evaluations of home support programs for
depressive symptoms targeting older African Americans
and which can be delivered by trained staff of a commu-
nity-based agency are non-existent. Cost analyses are
critical for evaluating the translational and implementa-
tion potential of such trials. We have calculated the cost
of delivering BTB by senior center staff trained in the
program (presented below); and we will calculate the
cost effectiveness of BTB from a societal perspective
that employs two relevant outcome measures: cost per
quality adjusted life year (QALY; Euro-QOL 5D vs.
health utility measures (HUI 2 and HUI3), and cost per
reduction in depression symptoms (PHQ-9). Cost-effec-
tiveness will be measured as the average incremental dif-
ference between cost of BTB and the control group
divided by the difference in health utility (measured as
QALYS) between treatment and control periods at 4
months, and at 8 months for the subsample of partici-
pants who receive BTB for the first 4 months and are
observed for another 4 months. Univariate and probabil-
istic sensitivity analyses will be conducted to determine
the incremental cost effectiveness of BTB at 8 months,
and will aid in determining the robustness of the model
when inpatient and outpatient medical and medication
costs are varied. As funds for the cost analyses were
obtained after the trial commenced, the cost analyses
will involve a subset (n = 130/208) of participants for
which we are able to collect QALY measures.
Recruitment and enrollment outcomes
Screening and enrollment results to date provide an
indication of the feasibility of the BTB trial. A total of
17 senior center care managers were trained to use the
PHQ-9 to screen for depression. Although screening
and enrollment is closed for this trial, the screening pro-
tocol has become fully integrated into routine intake
and reassessments across all senior center programs
including IHSP.
A total of 703 older adults were initially screened over
a 2 1/2 year recruitment period; 440 from IHSP; 263
from the community at-large (senior center members
and elsewhere). Of 703, 390 ( 5 5 % )s c o r e dp o s i t i v e l y
(PHQ-9 ≥ 5) and were eligible for the second screen. Of
440 from IHSP, 137 (31%) were eligible for the second
screen suggesting the importance of detection for this
medically compromised population. Of 263 community
at-large, 253 (96%) scored positively suggesting that
media and outreach efforts successfully targeted indivi-
duals with depressive symptoms, individuals correctly
self-identified as feeling depressed, and African
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a non-pharmacological trial.
Of the initial 390 positive screens, 279 (72%) were
successfully screened a second time of whom 192 (69%)
were eligible and willing to participate in BTB. Another
16 individuals with initially negative PHQ-9 scores were
screened 3 months later, became eligible, and enrolled
in the trial for a total of 208 participants. As these parti-
cipants contacted the study team prior to meeting the
targeted sample size, they were included in the trial.
Sample characteristics
Participants are on average 69.5 years, mostly single,
female, and with ≥ high school education. Over half
(67.79%) report some to a lot of difficulty paying for
basics, and have an average of 6.6 health conditions
with more than a third having diabetes (42.8%), high
blood pressure (78.8%), high cholesterol (58.2%), and
arthritis (76.4%). Only 19.2% were on an anti-depressant
medication and 16.8% on an anti-anxiety medication
whereas 52.9% were on pain medications. The average
second PHQ-9 score was 13 with 72% reporting moder-
ate to severe symptoms. (Table 3)
Program costs
The total cost of BTB, reported in 2010 dollars, was
obtained using a microcosting approach where total
costs represent the sum of microcosts in 3 main cate-
gories: screening, intervention delivery, and program
supervision. (Table 4) To capture costs, senior center
supervisors and interventionists kept detailed logs of
time spent conducting BTB tasks. Though double
screening over a two week period is required to confirm
trial eligibility, costs for the first screening only are
reported with the assumption that only one screening
would be performed if BTB is translated for real world
settings. Interventionists record real time in preparation,
documentation and implementation for each session
delivered in person or telephonically. Staff training time
for interventionists is also captured and converted to
costs based on application of hourly wage rates. Supervi-
sors of interventionists at the senior center account for
time spent with each interventionist in supervision.
Also, cost of managing adverse events during the trial,
such as suicidal ideations, is captured.
Time costs are monetized by multiplying time
required for each task for each participant, times the
wage rate plus fringe benefit costs of employees per-
forming the tasks. Wage rates and fringe benefit costs
(healthcare, disability, life insurance) are obtained
directly from employers (senior center and university).
Non-time related costs (program materials and mileage)
are also recorded. Material costs include study docu-
mentation forms and education print materials provided
to BTB participants. Interventionist travel expenses to
and from participants’ homes are captured per visit, and
monetized based on reimbursement at the current gov-
ernment rate ($0.55/mile).
The average screening cost is $2.63 per participant;
total cost of BTB (screening plus home intervention) is
$584.64 over 4 months, or $146.16 per participant, per
month. Time required delivering BTB at home ($197.31)
and labor and mileage costs associated with travel to
homes ($211.03) were the major contributors to total
model costs. Total cost of BTB compares favorably to
brand name antidepressants such as Paxil (paroxetine),
Zoloft (sertraline), or Cymbalta (duloxetine) which cost
approximately $100-$300 for a one-month supply [30].
Cost-effectiveness analyses of BTB from a societal per-
spective are currently underway.
Discussion
BTB is designed to improve access to mental health ser-
vices for older African Americans with depressive symp-
toms. This group represents a complex population as
they frequently suffer multiple chronic conditions which
place them at elevated depression risk, and have unmet
care management needs, financial and housing
Table 3 Baseline Characteristics of BTB Sample (N = 208)
Characteristic Mean (SD) %
Age
a 69.5 (8.7)
Sex
Male 22.1
Female 77.9
Education
< HS 21.2
HS/GED 29.3
> HS 49.5
Paying for basics
Not difficult at all 19.7
Not very difficult 12.5
Somewhat difficult 37.5
Very difficulty 30.3
Marital status
Single 88.0
Married 12.0
Number of health conditions 6.6 (3.5)
Antidepressant medication 19.2
Anxiety medication 16.8
Pain medication 52.9
PHQ9 Score (second screen) 13.0 (4.9)
Minimal/no depression (0-4) 0.0
Mild depression (5-9) 28.5
Moderate depression (10-14) 35.3
Moderate/severe depression (15-19) 24.2
Severe depression (≥ 20) 12.0
aN = 207.
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Page 8 of 11Table 4 Costs for Delivery of Beat the Blues to Treatment Group to Date (n = 122)
Description How Measured Mean Cost
Per
Participant
(SD)
Screening
A. Screening Cost Screening by a trained senior center care
manager staff
Time spent screening potential participants
multiplied by screener’s wage rate + fringe
benefit costs divided by sample size
$2.63
(1.51)
Intervention Delivery*
B. Intervention Delivery
Cost Per Person (Cost Per
Session X Number of
Sessions)
Intervention conducted by a trained senior center
staff member
Time conducting intervention multiplied by
wage rate of interventionist + fringe benefit
costs divided by sample size
$197.31
(133.00)
Participant Contact Outside
of Intervention Delivery
+
C. Total Cost of Contacts
Outside Intervention (Cost
Per Contact X Number of
Contacts)
All contact outside of the intervention by the
interventionist (telephone support, preparation
and documentation, mailing, faxing, and other)
Time spent in contact outside of intervention
multiplied by wage rate + fringe benefit costs of
interventionist divided by sample size
$84.00
(60.00)
Travel
Mileage Reimbursement
(Miles X $0.55)
Travel to and from homes of study participants by
interventionist
Miles traveled multiplied by mileage
reimbursement rate divided by sample size
$69.39
(46.88)
Labor Cost of Travel Travel to and from homes of study participants by
interventionist
Wage rate + fringe benefit costs of
interventionist multiplied by time spent in travel
divided by sample size
$141.64
(127.16)
D. Total Cost of Travel
(Mileage Reimbursement +
Labor Cost of Travel)
Total travel costs Sum of mileage reimbursement and labor cost
of travel
$211.03
Supervision Cost
Supervision of Screeners
~ Supervision of screeners by trained senior center
staff member
Wage rate + fringe benefit costs of supervisor
and screener multiplied by time spent
supervising employee then divided by sample
size
$4.19 (n/a)
Supervision of
Interventionists
&
Supervision of interventionist by social work
administrative staff of senior center
Wage rate + fringe benefit costs of supervisor
and interventionist multiplied by time spent
supervising employee then divided by sample
size
$22.33 (n/a)
E. Total Cost of Supervision
(Supervision by IHSP +
Supervision of
Interventionist)
Total supervision cost including supervisor
reviewing, meeting and managing screener,
meeting and managing interventionist, and
managing care mangers and service staff by
senior center
Sum or supervision of screeners and supervision
of interventionist
$26.52 (n/
a)
Training
#
F. Training Training of senior center screeners and of
interventionist to conduct intervention
Wage rate + fringe benefit costs of screeners
and trainers, multiplied by time spent in training
divided by sample size
$0.9 (n/a)
Materials
G. Materials All materials used by screeners and
interventionists
Cost of materials used for screening and during
the intervention divided by sample size
$61.93 (n/
a)
Adverse Events
H. Adverse Events Cost of adverse events Supervisor wage rate + fringe benefit costs,
multiplied by time spent dealing with adverse
events divided by sample size
$0.32
(1.09)
Total Cost of BTB Per Person
(A+B+C+D+E+F+G+H)
Total cost of delivering BTB (screening plus 4
month intervention) per participant
Sum of sub-cost categories $584.64
Total cost of delivering BTB intervention per
participant, per month
$146.16
* Represents: time spent delivering the intervention over the phone, in the home, or on site at the senior center
+ Represents: calls, visits, mailings, fax, preparation, documentation, see table below for detailed breakdown of costs
~ In the table, cost is presented on a per participant basis, supervision costs were not linked at the participant level and thus standard deviations are not
available. Cost of supervising screeners per supervisor (1) = $511.27 ($n/a). Cost of supervising screeners per screener (n = 17 screeners) = $34.97 (SD = 3.79).
&In the table, cost is presented on a per participant basis, supervision costs was not linked at the participant level and thus standard deviations are not available.
Cost of supervising interventionist per interventionist (5) = 544.78 ($278.89).
#Cost to train 4 interventionists = $117
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Page 9 of 11constraints and limited access to mental health service
options. Although clinical trials conducted in real world
settings involve complex strategies, decisions and trade-
offs, interventions tested in the setting intended for its
use may have greater potential for rapid implementation
and sustainability if proven efficacious and cost effective.
Rapid completion of recruitment and successful
enrollment, and high rate of detection of depressive
symptoms among IHSP and community members, sug-
gest that BTB resonates with the intended population.
As screening for depressive symptoms and delivery of
the home intervention has become normalized in senor
center daily operations as a consequence of this trial, it
appears feasible to integrate BTB in that setting and sus-
tain at least the screening phase. An added benefit of
embedding the trial in the senior center is that it results
in capacity building such that staff can continue to con-
duct depression detection after the research is com-
pleted. Because intervention components are delivered
in homes, BTB may appear resource-intensive. However,
direct costs suggest otherwise and compare more than
favorably to brand name antidepressants. Thus, feasibil-
ity of BTB as a practical trial embedded in a commu-
nity-based aging service center is demonstrated in these
important ways; success in training staff in depression
screening, response by the community to recruitment
efforts, enrollment of sample in 2 1/2 year period, low
cost of screening and delivery of the intervention.
Although enrollment is closed, trial procedures are in
progress. If BTB is efficacious and cost-effective, it will
represent a promising new approach for depression
detection and treatment for older African Americans
warranting replication and implementation in other
senior centers and the aging network in the USA. As
context was carefully considered in constructing and
testing BTB, its implementation and scalability potential
may be enhanced. The participating senior center and
research partner could serve as an implementation team
to train others nationally in the model for rapid pro-
gram expansion.
In conclusion, BTB was designed specifically for older
African Americans. However, the intervention compo-
nents and principles in which they are based (e.g., cli-
ent-centered, tailoring, behavioral activation) have high
relevance for other minority populations as well as
developing similar symptom management and preven-
tion programs for populations who may be hard-to-
reach and remain undertreated for chronic illness and
depression worldwide. Also, as a practical trial
embedded in a service/practice setting, it is designed to
build capacity in a community organization to engage in
depression detection and treatment. The lessons learned
from this collaborative academic-community partnership
can help inform developing needed behavioral interven-
tions for diverse older populations.
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